International Partnership for Microbicides, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: dapivirine

First Posted Date: 2022-06-13

Last Posted Date: 2024-07-03

Lead Sponsor: International Partnership for Microbicides, Inc.

Target Recruit Count: 124

Registration Number: NCT05416021

Locations: 🇿🇦
FARMOVS, Bloemfontein, South Africa

PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

Phase 1

Completed

Conditions: Bleeding
Safety Issues
Pharmacokinetics

Interventions: Combination Product: IPM Ring-105
Combination Product: IPM Ring-106

First Posted Date: 2021-09-13

Last Posted Date: 2024-11-05

Lead Sponsor: International Partnership for Microbicides, Inc.

Target Recruit Count: 40

Registration Number: NCT05041699

Locations: 🇺🇸
UPMC Magee-Womens Hospital, Center for Family Planning Research, Pittsburgh, Pennsylvania, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

Phase 1

Completed

Conditions: Contraception
Women
Healthy
Contraceptive Usage

First Posted Date: 2018-03-16

Last Posted Date: 2019-10-09

Lead Sponsor: International Partnership for Microbicides, Inc.

Target Recruit Count: 25

Registration Number: NCT03467347

Locations: 🇺🇸
Magee-Women'S Res Inst and Foundation, Pittsburgh, Pennsylvania, United States

A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

Phase 1

Completed

Conditions: HIV-1-infection

Interventions: Combination Product: Dapivirine Vaginal Ring, 25 mg
Combination Product: Dapivirine Vaginal Ring, 200 mg
Combination Product: Dapivirine Vaginal Ring, 100 mg

First Posted Date: 2017-07-31

Last Posted Date: 2019-01-29

Lead Sponsor: International Partnership for Microbicides, Inc.

Target Recruit Count: 49

Registration Number: NCT03234400

Locations: 🇺🇸
Bridge HIV CRS San Francisco Department of Public Health, San Francisco, California, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)

Phase 2

Withdrawn

Conditions: HIV-1-infection

Interventions: Drug: Truvada
Drug: Dapivirine

First Posted Date: 2017-03-09

Last Posted Date: 2017-09-08

Lead Sponsor: International Partnership for Microbicides, Inc.

Registration Number: NCT03074786

Locations: 🇿🇦
CAPRISA, eThekwini Clinical Research Site, Durban, KwaZulu-Natal, South Africa

Dapivirine Gel Rectal Safety and PK Study

Phase 1

Withdrawn

Conditions: HIV 1 Infection

Interventions: Drug: Dapivirine gel (0.05%)
Other: Universal HEC placebo gel

First Posted Date: 2017-02-07

Last Posted Date: 2017-02-08

Lead Sponsor: International Partnership for Microbicides, Inc.

Registration Number: NCT03044379

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring

Phase 1

Completed

Conditions: HIV Infections

Interventions: Combination Product: Placebo vaginal ring
Combination Product: Dapivirine Vaginal Ring

First Posted Date: 2016-09-30

Last Posted Date: 2017-09-08

Lead Sponsor: International Partnership for Microbicides, Inc.

Target Recruit Count: 16

Registration Number: NCT02920827

Locations: 🇧🇪
SGS Life Sciences Center, Antwerp, Flanders, Belgium

Evaluate the Safety & Assess Local and Systemic PK of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women

Phase 1

Completed

Conditions: HIV

Interventions: Drug: DS003 vaginal tablet
Drug: Placebo

First Posted Date: 2016-08-25

Last Posted Date: 2017-08-24

Lead Sponsor: International Partnership for Microbicides, Inc.

Target Recruit Count: 36

Registration Number: NCT02877979

To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women

Phase 3

Completed

Conditions: HIV Prevention

Interventions: Drug: Dapivirine Vaginal Ring-004

First Posted Date: 2016-08-10

Last Posted Date: 2022-10-25

Lead Sponsor: International Partnership for Microbicides, Inc.

Target Recruit Count: 941

Registration Number: NCT02862171

Locations: 🇿🇦
Madibeng Centre for Research, Brits, North West, South Africa
🇿🇦
Ndlovu Medical Centre, Elandsdoorn, South Africa
🇺🇬
MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda

and more 3 locations

A Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Dapivirine Vaginal Ring-004 and no tampons
Drug: Dapivirine Vaginal Ring-004 with tampons
Drug: Dapivirine Vaginal Ring-004 and same ring inserted after menses
Drug: Dapivirine Vaginal Ring-004 with no menses
Drug: Dapivirine Vaginal Ring-004 and new ring inserted after menses

First Posted Date: 2016-08-08

Last Posted Date: 2017-09-06

Lead Sponsor: International Partnership for Microbicides, Inc.

Target Recruit Count: 16

Registration Number: NCT02858024

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy